First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer

Journal of Nuclear Medicine

Volumn 54, Issue 3, 2013, Pages 380-387

  Barrett, John A ^a   Coleman, R Edward ^b   Goldsmith, Stanley J ^c   Vallabhajosula, Shankar ^c   Petry, Neil A ^b   Cho, Steve ^d   Armor, Thomas ^a   Stubbs, James B ^e   Maresca, Kevin P ^a   Stabin, Michael G ^e   Joyal, John L ^a   Eckelman, William C ^a   Babich, John W ^a  

^a A Subsidiary of Lantheus Holdings   (United States)

^b DUKE UNIVERSITY   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e Radiation Dosimetry Systems Inc   (United States)

Author keywords

Molecular imaging; Prostate cancer; Prostate specific membrane antigen

Indexed keywords

ABARELIX; BEVACIZUMAB; BICALUTAMIDE; DIETHYLSTILBESTROL; DOCETAXEL; FLUOROURACIL; FLUTAMIDE; GOSERELIN; HISTRELIN; HYDROCORTISONE; IODINE 123; IOFOLASTAT I 123; KETOCONAZOLE; LEUPRORELIN; MIP 1095 I 123; MITOXANTRONE; NILUTAMIDE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ABSENCE OF SIDE EFFECTS; AREA UNDER THE CURVE; ARTICLE; CHILL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; HISTOPATHOLOGY; HUMAN; INJECTION SITE IRRITATION; INSOMNIA; MALE; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MOLECULAR IMAGING; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION ABSORPTION; RADIATION DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEADY STATE;

AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; GLUTAMATES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; UREA;

EID: 84874820819     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.111203     Document Type: Article

References (33)

1. American Cancer Society Web site. Cancer facts and figures. http://www.cancer. org/Research/CancerFactsFigures/index. Accessed December 20, 2012.
2. National Cancer Institute Web site. SEER stat fact sheets: prostate. http://seer. cancer.gov/statfacts/html/prost.html. Accessed December 20, 2012.
3. Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2005;48:546-551. (Pubitemid 41278578)
4. Hövels AM, Heesakkers RA, Adang EM, et al. The diagnostic accuracy of CT and MR in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63:387-395.
5. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68-80. (Pubitemid 350166735)
6. 18F-fluoride on osteoblasts. Eur J Nucl Med Mol Imaging. 2006;33:491-494.
7. Ghosh A, Heston WDW. Tumor target prostate-specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528-539.
8. Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding prostate-specific membrane antigen. Cancer Res. 1993;53:227-230. (Pubitemid 23031827)
9. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7:927-935. (Pubitemid 18036141)
10. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81-85. (Pubitemid 27079448)
11. Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38:696- 701. (Pubitemid 46560805)
12. Troyer JK, Beckett ML, Wright GL. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate. 1997;30:232-242. (Pubitemid 27172834)
13. Milowsky MI, Nanus DN, Kostakoglu L, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007;25:540-547. (Pubitemid 350002961)
14. Vallabhajosula S, Goldsmith SJ, Kostakoglu L, et al. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res. 2005;11(19 pt 2):7195s- 7200s. (Pubitemid 41428723)
15. Foss CA, Mease RC, Fan H, et al. Radiolabeled small molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res. 2005;11:4022-4028. (Pubitemid 40791565)
16. Maresca KP, Hillier SM, Femia FJ, et al. A series of halogenated heterodimeric inhibitors of prostate-specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem. 2009;52:347-357.
17. Hillier SM, Maresca KP, Femia FJ, et al. Preclinical evaluation of novel glutamateurea- lysine analogs that target prostate specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009;69:6932-6940.
18. Kularatne SA, Zhou Z, Yang J, et al. Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted 99mTc-radioimaging agents. Mol Pharm. 2009;6:790-800.
19. Lu G, Maresca KP, Hillier SM, et al. Synthesis and SAR of 99mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates. Bioorg Med Chem Lett. In press.
20. Chen Y, Pullambhatla M, Foss CA, et al. 2-(3-{1-carboxy-5-[(6-[18F] fluoro-pyridine- 3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMAbased PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17: 7645-7653.
21. Banerjee SR, Pullambhatla M, Shallal H, et al. A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA). Oncotarget. 2011;2:1244-1253.
22. 18F-FECH. Eur J Nucl Med Mol Imaging. 2012;39:1085- 1086.
23. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys. 2003;85:294-310. (Pubitemid 36999340)
24. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027. (Pubitemid 43733519)
25. Kinoshita Y, Kuratsukuri K, Landas S, et al. Expression of prostate specific membrane antigen in normal and malignant human tissue. World J Surg. 2006;30:628-636.
26. Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of prostate- specific membrane antigen (PSMA) in tissue extracts and bodily fluids. Int J Cancer. 1995;62:552-558.
27. Moyer BR, Barrett JA. Biomarkers and imaging: physics and chemistry for noninvasive analyses. Bioanalysis. 2009;1:321-356.
28. Luthi-Carter R, Barczak AK, Speno H, Coyle JT. Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther. 1998;286:1020-1025. (Pubitemid 29003499)
29. Marchal C, Redondo M, Padilla M, et al. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. Histol Histopathol. 2004;19:715-718. (Pubitemid 38855052)
30. Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostatespecific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357-6362. (Pubitemid 38031820)
31. Wright GL Jr, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48:326-334. (Pubitemid 26279634)
32. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52:637-640. (Pubitemid 28440171)
33. Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol. 2007;31:1246-1255. (Pubitemid 47207130)